Recent Metformin Current Events | Metformin News
|
|
|
Sort By:
Relevance | Page Views |
A decade later, lifestyle changes or metformin still lower type 2 diabetes risk
Intensive lifestyle changes aimed at modest weight loss reduced the rate of developing type 2 diabetes by 34 percent compared with placebo in people at high risk for the disease, researchers conclude based on 10 years of data. view more (2009-10-29)
Diabetes drug kills cancer stem cells in combination treatment in mice
In a one-two punch, a familiar diabetes drug reduced tumors faster and prolonged remission in mice longer than chemotherapy alone by targeting cancer stem cells, Harvard Medical School researchers reported in the September 14 online first edition of Cancer Research, a journal of the American Association for Cancer Research. view more (2009-09-14)
UT Southwestern physicians bust myths about insulin
People diagnosed with type 2 diabetes often resist taking insulin because they fear gaining weight, developing low blood sugar and seeing their quality of life decline. view more (2009-08-11)
Pancreatic cancer risk decreased by one anti-diabetic therapy, increased by others
The antidiabetic medication metformin is associated with a reduced risk of pancreatic cancer in diabetics, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute. view more (2009-08-03)
M. D. Anderson study finds common diabetic therapy reduces risk of pancreatic cancer
Taking the most commonly-prescribed anti-diabetic drug, metformin, reduces an individual's risk of developing pancreatic cancer by 62 percent. view more (2009-08-03)
Benefit of glinides is not proven
The benefit of glinides in the treatment of type 2 diabetes is not scientifically proven. Nor do they perform better than other antidiabetics available in tablet form, such as metformin and sulfonylureas. view more (2009-06-18)
What is the relationship between hepatocellular carcinoma and type 2 diabetes mellitus?
Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide and the third leading cause of cancer-related deaths. view more (2009-06-12)
Death rates same for diabetes and heart disease patients receiving drug therapy or surgery
There is no difference in mortality among patients with type 2 diabetes and stable heart disease who received prompt bypass surgery or angioplasty compared to drug therapy alone, according to a landmark study focused exclusively on patients with both conditions. view more (2009-06-08)
Routine diabetes screenings could cut health-care costs
Screening adults for diabetes could result in significant cost-savings for health care systems compared to the costs of not screening individuals at all. view more (2009-06-08)
Common diabetes drug may 'revolutionize' cancer therapies
Researchers at McGill University and the University of Pennsylvania have discovered that a widely used anti-diabetic drug can boost the immune system and increase the potency of vaccines and cancer treatments. view more (2009-06-04)
Old diabetes drug teaches experts new tricks
Research from the Johns Hopkins Children's Center reveals that the drug most commonly used in type 2 diabetics who don't need insulin works on a much more basic level than once thought, treating persistently elevated blood sugar - the hallmark of type 2 diabetes - by regulating the genes that control its production. view more (2009-05-15)
Popular diabetes treatment could trigger pancreatitis, pancreatic cancer
A drug widely used to treat Type 2 diabetes may have unintended effects on the pancreas that could lead to a form of low-grade pancreatitis in some patients and a greater risk of pancreatic cancer in long-term users, UCLA researchers have found. view more (2009-05-01)
Glitazones have not yet been sufficiently investigated
There is so far a lack of scientific evidence that glitazones are better than alternative therapies at reducing mortality or complications caused by blood vessel damage in people with type 2 diabetes. view more (2009-04-02)
Long-term use of diabetes drugs by women significantly increases risk of fractures
A group of drugs commonly used to treat diabetes can double the risk of bone fractures in women, according to a new study by the University of East Anglia (UEA) and Wake Forest University. view more (2008-12-10)
If the diabetes has a direct carcinogenetic effect?
The association of DM2 with solid tumors, and particularly with HCC, has been long suspected and several studies have reported increased mortality rates for neoplastic diseases in patients with DM2. view more (2008-10-29)
Moderate use averts failure of type 2 diabetes drugs in animal model
Drugs widely used to treat type 2 diabetes may be more likely to keep working if they are used in moderation, researchers at Washington University School of Medicine in St. Louis have found in a study using an animal model. view more (2008-10-28)
Metformin increases pathologic complete response rates in breast cancer patients with diabetes
Metformin, the common first-line drug for type 2 diabetes, may be effective in increasing pathologic complete response rates in diabetic women with early stage breast cancer who took the drug during chemotherapy prior to having surgery, paving the way for further research of the drug as a potential cancer therapy, according to researchers at The... view more... (2008-06-03)
No 'convincing evidence' that glitazones work better than older diabetes drugs
There is no convincing evidence that the newer class of diabetes drugs, known as glitazones, offer real advantages over other diabetes drugs, when used on their own, concludes the Drug and Therapeutics Bulletin (DTB). view more (2008-04-10)
Diabetes medication and lifestyle changes can help treat weight gain induced by antipsychotic drugs
Lifestyle intervention and the drug metformin are both effective against antipsychotic-induced weight gain, and treatment is most effective when the two therapies are combined, according to a study in the January 9/16 issue of JAMA. view more (2008-01-09)
Researchers discover gene mutation thought to control energy levels
This study focused on the gene for AMPK (adenosine monophosphate-activated protein kinase), which controls the amount of energy in our cells by becoming active when fuel stores start to deplete, such as during exercise. view more (2007-09-19)
|
|
|
|
Sort By:
Relevance | Page Views |
|
